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Apoptotic pathways are regulated by protein-protein
interactions. Interaction of the BH3 domains of pro-
apoptotic Bcl-2 family proteins with the hydrophobic
groove of prosurvival proteins is critical. Whereas
some BH3 domains bind in a promiscuous manner,
others exhibit considerable selectivity and the se-
quence characteristics that distinguish these activi-
ties are unclear. In this study, crystal structures of
complexes between the prosurvival protein A1 and
the BH3 domains from Puma, Bmf, Bak, and Bid
have been solved. The structure of A1 is similar to
that of other prosurvival proteins, although features,
such as an acidic patch in the binding groove, may
allow specific therapeutic modulation of apoptosis.
Significant conformational plasticity was observed
in the intermolecular interactions and these differ-
ences explain some of the variation in affinity. This
study, in combination with published data, suggests
that interactions between conserved residues de-
marcate optimal binding.
INTRODUCTION
Apoptosis is a highly conserved process required for normal
growth and development, and the Bcl-2 family of proteins are
crucial regulators of this process. Cell fate is dependent on the
balance between prosurvival and proapoptotic members of
this family (Adams and Cory, 2007). Mammalian prosurvival
Bcl-2 proteins include Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1/
A1, each of which contains conserved sequence motifs called
Bcl-2 homology (BH) domains. The proapoptotic Bcl-2 family in-
cludes the multi-BH domain Bax-like proteins (Bax, Bak), which
are essential for cell death yet structurally similar to the prosur-
vival proteins, and the structurally diverse ‘‘BH3-only’’ proteins
(Hinds et al., 2007; Hinds andDay, 2005). The activation and olig-
omerization of Bax-like proteins in response to cytotoxic stimuli
commit the cell to death (Lindsten et al., 2000; Wei et al., 2001;
Zong et al., 2001).
BH3-only proteins (such as Bim, Puma, Noxa, Bmf, and Bid)
bear only a BH3 domain and are required for initiation of apopto-
sis (Huang and Strasser, 2000). However, the mechanism by
which BH3-only proteins activate apoptosis remains controver-
sial (Adams and Cory, 2007). In one model, prosurvival proteins818 Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights rsequester Bax-like proteins until they are displaced by interac-
tion of BH3-only proteins with the prosurvival proteins (Willis
et al., 2005). Others have suggested that the BH3-only proteins
directly interact with, and activate, the Bax-like proteins (Letai
et al., 2002). This model proposes that ‘‘activating’’ BH3-only
proteins are sequestered by prosurvival proteins until displaced
by ‘‘sensitizing’’ BH3-only proteins. In either case, binding of
BH3-only proteins to prosurvival proteins is required for activa-
tion of Bax-like proteins and subsequent cell death.
BH3-only proteins exhibit a range of binding selectivities, with
some binding all prosurvival Bcl-2 proteins whereas others bind
only a subset (Chen et al., 2005). For example, Noxa binds tightly
to Mcl-1 and A1 but not other prosurvival Bcl-2 proteins,
whereas Bad binds Bcl-2, Bcl-xL, and Bcl-w with high affinity.
All prosurvival proteins must be neutralized to initiate apoptotic
cell death, and those BH3-only proteins that can interact with
all prosurvival proteins (e.g., Bim and Puma) are potent killers.
In contrast, either Noxa or Bad, which have limited binding
profiles, are weak killers when acting alone, but together they
are potent (Chen et al., 2005).
The BH3 domain of BH3-only proteins forms an amphipathic
a helix that binds in a hydrophobic groove on the surface of
prosurvival Bcl-2 proteins (Petros et al., 2004). Although the
sequences of BH3 domains are variable, four hydrophobic resi-
dues together with an invariant aspartic acid, located between
the third and fourth hydrophobic residues, form the core of the
binding motif (Figure 1A). Systematic mutation of each residue
in the Bak BH3 domain suggested that these five residues are
the primary determinants of binding affinity (Sattler et al.,
1997). However, Lee et al. (2007) performed saturationmutagen-
esis of the second and fourth hydrophobic residues in the Bim
BH3 domain and found that a surprising range of mutants bound
tightly to each prosurvival protein tested but, in some cases,
a single residue change abolished binding. Together, these
results emphasize the difficulty of predicting how sequence dif-
ferences influence binding affinity and suggest that the context
of residues may be important.
Selective binding by prosurvival proteins to their cognate BH3-
only antagonists is being exploited to develop agents that can
induce apoptosis in cancer cells. In many tumors, prosurvival
Bcl-2 family members are overexpressed (Hanahan and Wein-
berg, 2000), yet the downstream apoptotic machinery is often
intact. Therefore, therapeutic agents that bind prosurvival pro-
teins can directly trigger cell death (Fesik, 2005). The BH3
mimetic ABT-737 binds tightly to Bcl-2, Bcl-xL, and Bcl-w, but
not to Mcl-1 or A1, and is active as a single agent against
some tumors, or in combination with other therapeutics, againsteserved
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of Mcl-1 or A1 was found to cause resistance to ABT-737, and
neutralization of Mcl-1 and A1 in combination with ABT-737
was required to trigger death in these cells (Konopleva et al.,
2006; van Delft et al., 2006). This suggests that the prosurvival
protein profile will determine susceptibility to BH3 mimetics.
An improved molecular understanding of how variations in BH3
domain sequence affect binding to prosurvival proteins will aid
the design of BH3 mimetics that target specific prosurvival
proteins.
Here we investigated the molecular basis for selective binding
by the prosurvival Bcl-2 protein A1. Human A1, which is primarily
expressed in hematopoietic tissues (Lin et al., 1993), is also
known as Bcl-2-related gene expressed in fetal liver (Bfl-1) and
is 72% identical to mouse A1 (Choi et al., 1995; Karsan et al.,
1996). There is only a single copy of A1 in humans, yet there
are four copies of A1 in the mouse genome (Choi et al., 1997;
Hatakeyama et al., 1998). Despite its redundancy, mice in which
just a single copy of A1 is disrupted have a phenotype indicating
that A1 protects from apoptosis (Hamasaki et al., 1998). More
recently, Simmons et al. (2008) found that, like Mcl-1 and Bcl-xL,
A1 can restrain Bak activation, preventing apoptosis. Consistent
with its prosurvival function and expression in hematopoietic tis-
sues, high levels of A1 are important for some B cell malignan-
cies (Brien et al., 2007; Morales et al., 2005).
To investigate how sequence differences in BH3 domains
affect interaction with prosurvival proteins, the structure of
mouse A1-a in complex with four BH3 domain peptides was
solved. The structure of A1 is very similar to that of other prosur-
vival proteins, except an acidic patch is found in the BH3 domain
Figure 1. BH3 Domain Peptides Bind with
Varying Affinity to A1DC
(A) Sequence alignment of the BH3 domain pep-
tides for which the interaction affinity with A1DC
was measured by ITC. The measured dissociation
constant is shown to the right of each sequence.
The arrow indicates the conserved aspartic acid,
and the conserved hydrophobic residues are
labeled H1–H4.
(B) A typical ITC result for a high-affinity interac-
tion, the Bim BH3 domain binding to A1DC, is
shown.
(C) A typical ITC result for a low-affinity interaction,
the Bmf BH3 domain binding to A1DC, is shown.
Experimental details are described in the Experi-
mental Procedures.
binding groove. Comparisons between
the A1:BH3 domain complexes allowed
a mutant of the low-affinity Bmf BH3 do-
main to be generated that bound with
higher affinity to A1.
RESULTS
Mutations Improve the Solubility
of A1
Mouse A1-a lacking the 20 residue C-
terminal hydrophobic transmembrane
domain (A1DC20) was only partially soluble when expressed
as a glutathione-S-transferase (GST) fusion protein (data not
shown). To improve the solubility of A1DC20, a mutagenesis
strategy similar to that used to improve the solubility of Bcl-w
was employed (Hinds et al., 2003). In brief, based on analysis
of sequence alignments with other prosurvival proteins, hydro-
phobic residues in A1 that were predicted to be solvent exposed
were mutated to a hydrophilic residue found at an equivalent
position in another prosurvival protein. In particular, mutation
of proline 104 to lysine greatly improved the solubility of
A1DC20 (data not shown). Although A1DC20 P104K alone was
still not soluble at high concentrations, heterodimerization with
BH3 domain peptides greatly improved the solubility of the com-
plex relative to free A1. To minimize disulfide bond formation and
further improve A1 protein stability, cysteine 113 was also mu-
tated to serine. A1DC20 containing both the P104K and C113S
mutations will subsequently be referred to as A1DC. The
P104K and C113S mutations are located on the a5-a6 loop
and are well removed from the BH3 domain binding groove.
BH3 Domain Peptides Bind to A1DC
with Varying Affinities
A1 interacts tightly with some BH3-only peptides (e.g., Bim and
Puma), yet only binds others weakly (e.g., Bmf) (Chen et al.,
2005). To analyze more fully the complex formed between A1
and various BH3-only proteins, we used isothermal titration
calorimetry (ITC) to measure directly the affinity of A1DC for
the mouse BH3 domain peptides (Figure 1A). The Puma, Bim,
NoxaA, Bid, and Bak BH3 domains bound tightly with dissocia-
tion constants ranging from <1 nM to 20 nM, whereas the BmfStructure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved 819
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Interactions with the Prosurvival Protein A1Table 1. Crystal Parameters and Data Collection and Refinement Statistics




Space group P21 P21212 P21 P21212 P21
Unit cell parameters
a, b, c (A˚) 49.64, 60.68, 59.99 66.65, 68.05, 32.14 44.24, 33.25, 58.51 61.74, 80.81, 32.18 49.54, 60.67, 60.01
a, b, g () 90, 109.5, 90 90, 90, 90 90, 104.7, 90 90, 90, 90 90, 109.4, 90
Data Collection Peak Inflection Remote













Multiplicity 6.4 (6.4) 4.0 (3.7) 4.7 (4.7) 3.6 (3.5) 6.4 6.3 4.4
Unique reflections 29,292 (4,253) 12,089 (1,720) 12,891 (1,824) 9,930 (1,411) 19,752 19,749 19,859
Completeness (%) 94.0 (93.9) 99.9 (99.8) 97.1 (95.0) 99.9 (99.9)
I/s 28.2 (9.6) 19.1 (2.9) 19.1 (2.9) 19.1 (2.2) 10.9 10.9 9.9
Rmerge 0.041 (0.165) 0.056 (0.365) 0.074 (0.456) 0.038 (0.554) 0.084 0.070 0.104
Refinement
Rfree/Rwork 0.210/0.183 0.231/0.191 0.229/0.182 0.242/0.207
Average B factor (A˚2) 21.3 21.9 18.3 48.8
Rmsd from ideal
Bond lengths (A˚) 0.011 0.012 0.010 0.010
Bond angles () 1.131 1.256 1.089 1.161
Ramachandran plot
Most favored (%) 96.4 96.1 92.5 90.6
Allowed (%) 3.6 3.9 6.9 8.2
Generously
allowed (%)
0.0 0.0 0.0 1.3




2 1 1 1
Number of water
molecules
176 49 122 25
Number of ions 2 2 0 1
Number of hetero
(not water or ions)
0 0 18 0
Values in parentheses are the statistics for the highest resolution shell.BH3 domain bound more weakly to A1DC, with a dissociation
constant of 180 nM. Typical titration curves for a tight (e.g.,
Bim BH3) and weak (e.g., Bmf BH3) A1DC interaction are shown
in Figures 1B and 1C, respectively. The dissociation constants
reported here are very similar to those calculated using the
Cheng-Prusoff equation (Cheng and Prusoff, 1973) from the
IC50 values reported by Chen et al. (2005). Because A1DC in
complex with a number of BH3 domain peptides had good solu-
tion properties, we sought to identify the molecular basis for the
observed differences in affinity by solving the structures.
Crystallization and Structure Determination of A1DC
in Complex with the Puma BH3 Domain Peptide
A1DC could not be crystallized alone due to its propensity
to aggregate. Therefore, the structure of A1DC was solved in820 Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights rcomplex with a peptide that spanned the Puma BH3 domain
(A1DC:Puma). The Puma BH3 domain used for crystallization
was produced by recombinant methods that depended on cyan-
ogen bromide proteolysis. To prevent inappropriate cleavage,
Met144 in Puma was mutated to isoleucine, which is commonly
found at this position. Puma M144I bound with the same affinity
as wild-type to A1DC (KD < 1 nM) and was used in crystallization
trials. Subsequent references to the PumaBH3domain will mean
Puma M144I. Crystals of A1DC:Puma that diffracted to high
resolution grew in a monoclinic space group and contained
two A1DC complexes in the asymmetric unit. To obtain initial
phases, two multiwavelength anomalous diffraction (MAD) data
sets were collected from crystals containing selenomethionine
(SeMet)-labeled A1DC (Table 1). The structure of A1DC:Puma
was solved using the lower-resolution MAD data set and refinedeserved
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A1DC:Puma was solved by molecular replacement to confirm
that SeMet incorporation did not affect the complex (data not
shown). A summary of the data collection and refinement statis-
tics are given in Table 1.
The Structure of A1DC in Complex with the Puma
BH3 Domain Peptide
The structure of the A1DC:Puma complex is shown in Figure 2A.
A1DC contains eight helices arranged around the central hydro-
phobic helix a5 in a similar arrangement to that observed in other
prosurvival proteins (Hinds and Day, 2005; Petros et al., 2004).
Helices a4, a5, and a6 form an almost parallel three-helical bun-
dle, while helices a1 and a2 are almost perpendicular to each
other and to a5. The Puma BH3 domain is bound to A1DC in
the same orientation as observed for other BH3 domains when
bound to prosurvival proteins (Czabotar et al., 2007; Petros
et al., 2004). Residues located on a5 and a8 form the base of
the BH3 domain binding groove, while residues on a2, a3, and
a4 form the sides of the groove.
Despite similarities between the overall topology of A1 and
other prosurvival proteins, A1DC has distinct features. Helix a1
in A1DC is longer than that seen in Bcl-2, Bcl-xL, and Bcl-w,
and its length and position are most similar to Mcl-1
(Figure 2B). Although the a1-a2 loop in A1 is shorter than in the
other prosurvival proteins, its conformation differs slightly
between the two molecules in the asymmetric unit and it is not
completely ordered in either (Figures 2A and 2B and data not
shown), suggesting that it is flexible and capable of adopting
multiple configurations. The presence of a short a3 and an ex-
tended a2 distinguishes A1 from other prosurvival proteins
(Figure 2B). A1 also contains insertions in the loops between
a3-a4, a5-a6, and a7-a8 (Figure 2B). The insertion prior to a6
results in a longer poorly defined a5-a6 loop, but the position
of the N terminus of a6 in both molecules is similar and compa-
rable to that observed in other prosurvival protein complexes
(Czabotar et al., 2007; Liu et al., 2003). The one residue insertion
in the first turn of a8 in A1 disrupts the a-helical hydrogen bond-
ing, although the turn is still helical and has a similar position to
that observed in other prosurvival proteins.
The conserved residues of the BH3 domain occupy compara-
ble positions in the groove of all prosurvival proteins (Czabotar
et al., 2007; Petros et al., 2004). For example, the conserved as-
partic acid in the BH3 domain has remarkably similar contacts
even though the a4-a5 loop in A1 and Mcl-1 contains an extra
residue compared to Bcl-xL, Bcl-w, and Bcl-2 (Figures 2B and
3). The four hydrophobic residues also fit into similar pockets
(Figure 3). However, in contrast to the Bcl-xL:Bim complex (Liu
et al., 2003), where the second and fourth hydrophobic residues
occupy deep pockets, in A1 the first and second hydrophobic
pockets are deepest, whereas the fourth hydrophobic residue
of the Puma BH3 domain is bound to a shallow pocket. This con-
figuration is similar to that observed in the Mcl-1:Bim complex
(Czabotar et al., 2007), yet the leucine pocket in A1 is distin-
guished in two ways. First, the hydrophobic surface provided
by Val48 in A1 is provided by Phe105 in Bcl-xL and Phe228 in
Mcl-1, and in both cases the Phe is located four residues down-
stream relative to Val48 in A1 (Figure 2B), indicating that residues
in different positions can fulfill similar roles. Second, in contrastStructurto other prosurvival homologs that have an entirely hydrophobic
pocket, Glu78 is found in the leucine pocket in A1 (Figure 2B).
Electrostatic calculations performed with the BH3 domain omit-
ted from A1 show that Glu78 introduces a significant negative
charge into the BH3 domain binding groove (Figure 4A). This is
in contrast to Mcl-1, which has a positive charge in its groove
(Czabotar et al., 2007; Day et al., 2005), or Bcl-2, Bcl-xL, and
Bcl-w, in which the binding groove is hydrophobic (Petros
et al., 2004).
Buried charges are energetically unfavorable (Dao-pin et al.,
1991a), suggesting that Glu78 is likely to be protonated in the
complex. To determine whether protonation of Glu78 accom-
panies peptide binding, the interaction of A1DC with Bim and
Puma BH3 domain peptides was quantitated using ITC in buffers
with different enthalpies of ionization (Jelesarov and Bosshard,
1999; Figure 4B). In this experiment, the slope observed corre-
sponds to the change in protonation upon binding. For the Bim
and Puma BH3 domain peptides, the slope was found to be
1.11 and 0.92, respectively, indicating that when a complex
forms between A1 and a BH3 domain peptide, a single group
is protonated. To identify the groups involved, the pKa values
of all titratable residues in A1 and the Puma BH3 domain were
calculated using continuum electrostatics in the bound and
unbound state (Alexov and Gunner, 1997; Georgescu et al.,
2002). Glu78 in A1 was the only residue for which a significant
difference in protonation state at physiological pH was calcu-
lated. The calculated pKa rose from 4.6 in the unbound state to
8.0 in the bound form, indicating Glu78 introduces a negative
charge into the groove in unliganded A1 but is protonated
when bound to a ligand.
Each BH3 Domain Has Distinct Interactions with A1
To identify the molecular basis for the observed differences in
affinity and to understand the features that allow some peptides
to bind in a promiscuous manner whereas others have a more
restricted binding profile, structures of A1DC in complex with
other BH3 domain peptides were also determined. A1DC was
purified in complex with Bim, Bmf, Bak, Bid, and NoxaA BH3
domains, and crystals of A1DC in complex with Bmf, Bak, and
Bid that diffracted to high resolution were obtained (Table 1).
The crystals of A1DC in complex with Bak, Bmf, and Bid BH3
domains were grown under similar crystallization conditions, yet
eachcomplex haduniqueunit cell parameters. In theA1DC:Puma
complex crystals, the peptides from the two complexes in the
asymmetric unit back onto each other in an antiparallel fashion
(data not shown) and contribute to crystal packing. Although the
Bmf, Bid, and Bak BH3 domain peptides also make crystal
contacts, the crystals of these complexes contained only one
complex in the asymmetric unit. Importantly, in all cases, the sim-
ilarity of the interactions betweenA1DCand the peptide suggests
that the conformation is not affected by the crystal contacts.
The A1DC:Bmf, A1DC:Bak, and A1DC:Bid complex structures
were solved by molecular replacement (Table 1). The A1:Puma,
A1:Bmf, and A1:Bak structures are of similar quality, but the
A1:Bid structure is slightly lower resolution and has a higher
average B factor. The average B factor from refinement of the
A1:Bid structure is comparable to the B factor calculated from
the Wilson plot (46.1 A˚2). The structures were very similar to
the A1:Puma complex, with root-mean-square deviationse 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved 821
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Interactions with the Prosurvival Protein A1Figure 2. A1 Forms an a-Helical Bundle Similar to other Prosurvival Bcl-2 Proteins
(A) The structure of one A1:Puma complex in the asymmetric unit is shown. A1DC contains eight a helices, a1–a8. The Puma BH3 domain (yellow) is bound to the
BH3 domain binding groove formed by helices a2–a5 and a8 in A1DC.
(B) A structure-based sequence alignment of A1 with Mcl-1 (Protein Data Bank code: 2NL9), Bcl-w (1O0L), Bcl-xL (1PQ1), and Bcl-2 (1G5M). The positions of
Val48 in A1, and the phenylalanine in Mcl-1 and Bcl-xL that forms equivalent interactions with the bound BH3 domain, are indicated by arrows, while Glu78 in
A1 is also indicated (*). The mouse Mcl-1 sequence is shown with the residues that have been mutated to the human sequence underlined (hm, humanized
mouse). Other sequences are mouse or human as indicated.822 Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved
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Interactions with the Prosurvival Protein A1(rmsd) of 0.69 and 0.58 A˚ for the A1:Bak and A1:Bid structures,
respectively, when the Ca atoms of residues 1–24, 31–106,
and 113–149 in A1 and the equivalent of residues 132–153 in
the Puma BH3 domain were compared. The Ca rmsd of the
A1:Bmf complex when compared in a similar manner to the
A1:Puma structure was 3.19 A˚. However, when the Bmf peptide
was omitted from the comparison, the Ca rmsd dropped to
0.67 A˚, indicating that the low-affinity Bmf peptide is bound in
a different manner to A1 from the other BH3 domain peptides.
To identify the features that allow diverse sequences to bind
with high affinity to the same groove, all contacts of 4.0 A˚ or
less between A1 and each BH3 domain were determined (Fig-
ure 5). Equivalent contacts, where the same residue in A1 con-
tacts the equivalent BH3 domain residue in all the complexes,
primarily involve residues in a4 and a5. Despite the underlying
sequence variation of the ligands, eight residues in these helices
(Gln73, Val74, Met75, Glu78, Asn85, Gly87, Arg88, and Thr 91)
form at least one equivalent contact with all the BH3 domains.
Figure 3. Prosurvival Proteins Have Similar
Contacts with Conserved Residues
The interactions formed by A1, Bcl-xL (Protein
Data Bank code: 1PQ1), and Mcl-1 (2NL9) with
the strictly conserved aspartic acid in the BH3
domain are almost identical (upper panel). More
variation is observed in the interactions with the
conserved leucine in the BH3 domain (lower
panel).
Figure 4. A1 Has a Negative Charge in the Binding Groove that Is
Protonated upon Interaction with a BH3 Domain
(A) A solvent-accessible surface colored by electrostatic potential (<10 kT/e
and >10 kT/e) shows that A1 has a negative charge in the BH3 domain binding
groove. The Puma BH3 domain peptide is shown in yellow.
(B) ITC was used to measure the total enthalpy of interaction between A1, and
the Bim and Puma BH3 domains in buffers with different enthalpies of ioniza-
tion (phosphate, 1.22 kcal/mol; PIPES, 2.74 kcal/mol; HEPES, 5.02 kcal/mol)
at pH 7.5. The slope of the line (1.11 and 0.92 for the Bim and Puma BH3
domains, respectively) indicates the number of protonations.
Four of these residues participate in mul-
tiple equivalent contacts, indicating that
not only do the helices have similar posi-
tions but that the side chains fulfill a con-
served function. In contrast, only three
residues from helices a2 and a3 (Val48,
Leu52, and Tyr55) form equivalent con-
tacts in all the complexes. The plasticity of the interactions
between a2 and a3, and the BH3 domains is exemplified by
Glu47 (a2), which interacts with residues that are separated by
ten amino acids in the BH3 domain sequences (Figure 6).
To investigate the differences between the complexes in more
detail, each complex was superimposed onto onemolecule from
the A1DC:Puma structure. The superposition was performed in
two stages to ensure that the most similar regions of the struc-
ture were optimally aligned (see the Experimental Procedures).
Superposition of the two A1DC:Puma complexes revealed the
intrinsic variation of the structures and allowed the significance
of the observed differences to be evaluated.
The A1 structures are very alike (Figure 7A), and the Puma,
Bak, and Bid BH3 domain peptides are bound to A1DC in an
almost identical position (Figure 7B). However, the Bmf BH3
domain, which binds weakly to A1DC, is oriented slightly differ-
ently. A rotation of approximately 4, as indicated in Figure 7B,
results in an average Ca displacement of 0.3 A˚ compared to
the Puma BH3 domain, although the Bmf BH3 domain still packs
tightly in the groove of A1. As a consequence of the altered
orientation of Bmf, the conserved aspartic acid in the Bmf BH3
domain does not interact with Arg88 or Asn85 in A1 as observed
for other BH3 domain peptides (Figure 7C). Instead, Asp143 in
the Bmf BH3 domain interacts with Arg147 on the same face
of the helix. Although the density for the carboxyl group of
Asp143 was weak (see Figure S1 in the Supplemental Data avail-
able with this article online), the change in orientation of the BH3
domain helix increased the distance between Asp143 and Arg88
such that the length of a salt bridge would be over 4.4 A˚. Instead,
several water molecules hydrogen bond to Arg88 in A1DC.
Sattler et al. (1997) showed that mutation of the conserved
aspartic acid significantly weakened the interaction between
Bcl-xL and the Bak BH3 domain. Therefore, the reduced affinity
of the A1DC:Bmf interaction is probably due, in part, to the ab-
sence of interactions between Asp143 in Bmf and Asn85 and
Arg88 in A1DC. Both the conserved aspartic acid in the bound
BH3 domain and Asp81 normally interact with Arg88 in A1, form-
ing a salt-linked triad. Such triads are energetically favorable due
to the reduced entropic cost relative to forming a single salt
bridge (Dao-pin et al., 1991b; Horovitz et al., 1990).Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved 823
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Interactions with the Prosurvival Protein A1Figure 5. The Bound BH3 Domains All Have Similar Contacts with a4 and a5, but Contacts with a2 and a3 in A1 Are Variable
All residues in A1 that are within 4 A˚ of the BH3 domain (yellow) are shownwith a line to indicate the interaction. Residues in A1 are colored as in Figure 2. H bonds
are indicated with green lines and salt bridges by red lines in all panels. Gray lines in the A1DC:Puma panel indicate that a contact is present in only one complex in
the asymmetric unit, while a black line indicates that the contact is present in both complexes in the asymmetric unit.824 Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved
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Peptide Modulate Affinity
To determine differences that might contribute to the altered
orientation of the Bmf BH3 domain, we identified contacts that
were present in all the high-affinity complexes but were absent
in the A1:Bmf complex. Of the five missing contacts, two involve
Asp143 (Figure 5), whereas two others involve hydrophobic
residues and the absence of these probably occurs as a conse-
quence of the altered orientation of the Bmf BH3 domain. The
remaining conserved contact that is missing involves Lys147
in A1, a residue that interacts with Asn149 in the Puma BH3
domain, Asn83 in the Bak BH3 domain, and Asp98 in the Bid
BH3 domain, but not with the equivalent residue, His146, in the
Bmf BH3 domain (Figures 5 and 8A). Instead, His146 interacts
with a chloride ion which occupies the position of the side chain
of Asn149 fromPuma. TheBH3 domain of Bmf in which His146 is
mutated to asparagine, a residue that could potentially hydrogen
bond to Lys147 in A1, binds approximately 5-fold more tightly
than the wild-type (Figure 8B), demonstrating that contacts at
the C terminus of the peptide contribute to binding.
Additional differences were observed in the interactions
formed by the C terminus of the Bmf BH3 domain (Figure 8A).
Notably, Phe148 in A1 is displaced when Bmf is bound
(Figure 8A). This may be because Phe145 in the fourth hydropho-
bic position has a different location from that observed in the
high-affinity complexes. Whereas Phe145 in Bmf may exacer-
bate the weak interaction with A1DC, it is itself unlikely to reduce
the affinity because the Bim BH3 domain binds tightly to all the
prosurvival proteins (Chen et al., 2005) and it also has a phenylal-
anine in the fourth hydrophobic position. To evaluate the role of
Phe145, mutant Bmf peptides were made that were predicted to
alleviate the clash due to Phe145 (F145L), or introduce anH bond
Figure 6. Variable Contacts Are Formed between a2 and the BH3
Domains
Each panel shows the same residues in A1 and the equivalent residues in the
BH3 domain (yellow) that are involved in contacts in at least one complex. The
contacts with Glu47 are the most variable and are labeled.Structureto a2 in A1 (H149Y), but neither strengthened the interaction with
A1 (Figure 8B). Further studies will be required to determine
whether other interactions at the C terminus of the BH3 domain
influence the affinity of the interaction. However, the variability
seen at the C terminus of the bound BH3 domain emphasizes
the plastic nature of the binding groove.
DISCUSSION
To understand how the prosurvival Bcl-2 protein A1 binds
ligands of diverse sequences, we determined the structure of
A1 in complex with peptides that span the binding region of
four proapoptotic Bcl-2 proteins. These structures are the
most complete set of prosurvival Bcl-2 protein:BH3 domain
complexes solved to date and allow a detailed analysis of bind-
ing. Considerable conformational plasticity accommodates
sequence variation in the BH3 ligand and significant variability
was observed in the intermolecular interactions in the four
A1DC:BH3 domain complexes. These differences help rational-
ize the binding specificity of A1.
The helical structure of A1 is typical of that seen in other pro-
survival Bcl-2 proteins and varies little between the complexes
(Figures 2 and 7). As the BH3 domain binding profile of A1 is
most similar to that of Mcl-1 (Chen et al., 2005), it is not surprising
that its binding groove is also similar to that of Mcl-1. However,
their binding profiles differ and the presence of several sequence
differences, including insertions, must underpin this (Figure 2B).
Notably, A1 has an acidic residue, Glu78, in the binding groove.
Other prosurvival proteins have a hydrophobic (Petros et al.,
2004) or slightly positive (Day et al., 2005; Czabotar et al.,
2007) groove. As it is unfavorable to bury a charge (Dao-pin
et al., 1991a), it was expected that Glu78 would be protonated
when ligands are bound. Protonation was shown to accompany
binding (Figure 4B), and structure-based pKa calculations sug-
gest that Glu78 is the only residue that is protonated upon bind-
ing BH3 domains. Indeed, it is unlikely that any helical peptide
ligand could form a salt bridge to Glu78 because the side chains
of lysine and arginine could not be accommodated in the groove
near Glu78.
Despite significant variability in the interface interactions, the
overall properties of each A1:BH3 domain interface are very sim-
ilar. In all four structures, the interface is between 846 and
1028 A˚2 and the shape correlation statistic (Lawrence and
Colman, 1993) varies between 0.699 and 0.782. Each BH3 do-
main forms between 37 and 44 contacts with A1, and 16 of these
contacts are maintained across all four A1DC:BH3 domain com-
plexes (Figure 5). These conserved contacts mainly involve res-
idues in helices a4 and a5, with only a minority arising from res-
idues located on a2, a3, or the associated loops (Figure 5). In
total, residues in a4 and a5 contribute between 45% and 52%
of the total A1 surface area that is buried upon complex forma-
tion, and 86%–89% of this is due to equivalent interactions.
The conserved nature of the interactions suggests that contacts
to residues in a4 and a5 underpin binding.
To understand the basis of weak binding, we analyzed the
structure of A1DC:Bmf in detail. Although the buried surface
area is similar to that in the high-affinity complexes, the align-
ment of the Bmf BH3 domain in the groove is slightly different
and this appears significant (Figure 7B). Contacts involving16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved 825
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Interactions with the Prosurvival Protein A1Lys147 may contribute to this. In the Puma BH3 domain, Asn149
interacts with Lys147 in A1 whereas the equivalent interaction in
the A1:Bmf complex, which would involve His146, is absent. This
contact appears to be critical because the affinity of Bmf with the
H146N mutation for A1 is increased 5-fold (170 nM versus 35
nM). The prosurvival proteins that Bmf binds tightly, Bcl-2, Bcl-
xL, and Bcl-w, all have a tyrosine at the equivalent position of
Phe148 in A1, which would be predicted to interact with
His146 in the Bmf BH3 domain. The significant effect this muta-
tion has on the affinity suggests that it may have an indirect effect
and is possibly important for positioning the peptide.
In addition to the Bmf H146N mutant, mutations in the Noxa
and Bad BH3 domains have been shown to improve their in-
teraction with Bcl-xL and Mcl-1, respectively, and these might
also enhance the position of the BH3 domain (Chen et al.,
2005; Day et al., 2005). For example, mutation of Lys35 to gluta-
mic acid in the human Noxa BH3 domain, and Ser113 to glycine
in the mouse Bad BH3 domain, strengthens their interaction with
Bcl-xL and Mcl-1, respectively (Chen et al., 2005; Day et al.,
2005). These changes were designed to minimize unfavorable
contacts but, analogous to the observations with Bmf, these
changes may influence the position of the ligand. Likewise, mu-
tation of Tyr105 in the Bad BH3 domain, or Phe32 in the Noxa
BH3 domain to isoleucine, improves the affinity of these BH3
domains for specific prosurvival proteins (Chen et al., 2005;
Day et al., 2005). These residues are in the conserved H1 and
H3 positions in the BH3 domains, and in each case mutation to
isoleucine was designed to prevent clashes with the H1 and
H3 pockets in the prosurvival protein. Although the mutations
Figure 7. The A1:BH3 Domain Complexes
Are Similar, but the Bmf BH3 Domain Does
Not Form Conserved Interactions
(A) Each A1:BH3 domain complex was superim-
posed onto the A1:Puma complex. No significant
differences are observed in the main chain of A1
when bound to different BH3 domain peptides.
The Ca traces of A1 from the A1:Puma (light and
dark blue), A1:Bak (yellow), A1:Bid (red), and
A1:Bmf (green) complexes are shown.
(B) The Bmf BH3 domain is bound to A1 at a differ-
ent orientation from other BH3 domain peptides.
The surface of A1 from one A1:Puma complex is
shown with the main chain of all the BH3 domain
peptides after superposition as in (A). The direc-
tion of rotation of the Bmf BH3 domain (green) is
indicated.
(C) Interactions between A1 and the conserved
leucine and aspartic acid in the BH3 domain are
shown for each complex.
that improve ligand binding are dispersed
throughout the BH3 domain, they may all
improve interactions involving the con-
served residues.
The explicit contribution of each hydro-
phobic residue to the interaction may de-
pend on its context. That is, the contribu-
tion of individual residues may depend on
the surrounding residues, and a given dif-
ferencemaybe tolerated if theBH3domain formsmany favorable
interactions with the prosurvival protein. Recently it was shown
that Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 could accommodate a sur-
prising range of residues in theH2 andH4positions in the context
of the Bim BH3 domain (Lee et al., 2007). For example, mutation
of the H2 residue to isoleucine, methionine, or phenylalanine only
slightly reduced binding to any of the prosurvival proteins. Even
less conservativemutations, suchasmutationofH2 to serine, still
bound tightly to some prosurvival proteins. The Bim BH3 domain
binds tightly to all the prosurvival Bcl-2 proteins and itmaybe that
somemutations were tolerated because the changes were intro-
duced in a strong binding context. In a BH3 domain that does not
bind tightly to all prosurvival proteins, for example the Bak BH3
domain used by Sattler et al. (1997) or the Bid BH3 domain
used here, mutation of the H2 and H4 residues may not be as
well tolerated.
The model of apoptosis regulation proposed by Willis et al.
(2005) suggests that Bax and Bak are maintained in an inactive
state through their interaction with prosurvival proteins. In partic-
ular, Bcl-xL and Mcl-1 were found to bind tightly to Bak in vitro
and restrain Bak in healthy cells. Recently, Simmons et al.
(2008) found that A1 can bind and prevent activation of Bak,
but not Bax, in vivo. This is consistent with the tight interaction
we observed between A1 and the Bak BH3 domain (Figure 1).
According to the indirect model, for cell death to occur, Bak
must be displaced from the prosurvival proteins by BH3-only
proteins (Adams and Cory, 2007). It is not apparent how this is
achieved, but differences in the A1DC:Bak BH3 domain complex
may provide clues. For example, a slight translocation of a2 and826 Structure 16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved
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Interactions with the Prosurvival Protein A1a3 in the A1DC:Bak complex, delimited by Glu47 and Phe59, is
observed relative to their position in the other A1DC complexes.
Residues in the Bak BH3 domain such as Arg85 and Val71 that
interact with this part of A1 are conserved in Bak, but are rarely
present in the BH3 domains of BH3-only proteins (Figure S2).
These features may serve to distinguish prosurvival complexes
that contain Bak, and act as a trigger point for displacement.
An improved understanding of the process by which Bak is
displaced requires further studies, ideally with intact proteins.
To initiate apoptosis in tumor cells, recent drug discovery
efforts have focused on the BH3 domain binding grooves of
the prosurvival Bcl-2 proteins (Fesik, 2005). The Bcl-2 family
antagonist ABT-737 (Oltersdorf et al., 2005; Petros et al., 2006)
was developed as a Bad BH3 domain mimetic and, as predicted
based on the binding profile of Bad, it only binds Bcl-2, Bcl-xL,
and Bcl-2, but not Mcl-1 or A1. Consistent with this, expression
of Mcl-1 or A1 has been found to prevent cell death induced by
ABT-737 (Konopleva et al., 2006; van Delft et al., 2006). Because
the binding grooves of A1 and Mcl-1 are similar, the structure of
A1 solved here, in addition to that of Mcl-1, may allow develop-
ment of therapeutics that can target Mcl-1 and A1. Mouse A1
was used in this study but the residues that comprise the binding
groove of human A1 are almost identical (Figure S3). In particu-
Figure 8. His146 in the Bmf BH3 Domain Does Not Interact
with Lys147 in A1
(A) The residues at the position equivalent to His146 in Bmf in other BH3
domain peptides interact with Lys147 in A1. Phe148 in the A1:Bmf complex
has also shifted relative to its position in other A1 complexes to accommodate
F145 in the Bmf BH3 domain.
(B) The affinities of Bmf wild-type and mutant BH3 domain peptides for A1
were determined using ITC.Structurelar, Glu78, which introduces the negative charge into the BH3
domain binding groove, is present in human A1. To develop mol-
ecules that only bind to human A1, it may be possible to exploit
the acidic feature in the BH3 domain binding groove.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Mouse A1 (GenBank accession number U23774) with a 20 residue C-terminal
truncation and containing the P104K and C113S mutations was expressed as
a GST fusion using pGex 6P-3. A1DCwas expressed in BL21 (DE3) containing
a plasmid that expressed extra copies of the argU and ileX tRNAs (Kim et al.,
1998). After induction with 0.2 mM IPTG, A1DC was expressed for 16 hr at
18C and the cells were lysed in 20 mM Tris (pH 8.5), 150 mM NaCl. Following
purification using glutathione resin, A1DC was exchanged into PBS and the
GST was released by proteolysis. A1DC contained the N-terminal vector-de-
rived residues GPLGS after digestion with PreScission protease. A1DC was
subsequently purified by gel filtration using a Superdex 75 column. Samples
used for crystallization were further purified by anion exchange using a Re-
sourceQ column. SeMet-labeled A1DC was prepared using the method of
Studier (2005). The same BL21 strain used previously to minimize codon
bias was grown in PASM-5052 at 18C until saturation. SeMet A1DC was pu-
rified as for the unlabeled protein, and SeMet incorporation was verified by
mass spectrometry. Mouse Puma M144I, Bim, Bmf, NoxaA, and Bak BH3 do-
main peptides were produced as described previously (Hinds et al., 2007). The
sole methionine in the Puma BH3 domain peptide (Met144) was substituted for
an isoleucine. Chromatography reagents were supplied by GE Healthcare.
Isothermal Titration Calorimetry
ITC experiments were performed using a VP-ITC instrument (MicroCal) at
25C. BH3 domain peptides were resuspended at 1–3 mM in water and quan-
titated using the absorbance at 205 nm. A1DC was dialyzed into PBS and
quantitated. The peptide was diluted to the desired concentration using
PBS, whereas A1DC was diluted using PBS and water to match the peptide
buffer (PBS comprised greater than 94% of the final solution in all cases).
For the relatively weak interactions, A1 was diluted to 10 mM and the BH3
domain peptide to 120 mMwith 10 ml injections of peptide. For the high-affinity
interactions, A1DC was diluted to 5 mM and the peptide to 40 mM, and two dif-
ferent injection volumes were used to obtain more points during saturation. In-
jections of 10 ml were used, except for a ligand stoichiometry of 0.8:1.2, where
4 ml injections were used. The data were analyzed using Origin 7 and fit to a
single site binding model. The Cheng-Prusoff equation was used to calculate
the dissociation constants from IC50 values reported by Chen et al. (2005):
KD =
IC50
1+ A½ =KA ;
where KD is the dissociation constant of the inhibitory peptide, IC50 is the inhib-
itor concentration that halves binding, [A] is the concentration of the binding
peptide, and KA is the dissociation constant of the binding peptide for the pro-
survival protein. Because the binding peptide was immobilized on a chip, its
concentration cannot be directly determined. Therefore, the reported KD and
IC50 values for the interaction between Bim and A1 were used to derive a value
for [A] of 3.8 nM. This calculated value is assumed to be constant. The disso-
ciation constants for the interaction between A1 and Puma (0.7 nM), Bmf
(210 nM), Bad (1700 nM), Bid (1.1 nM), and Noxa (21 nM) were calculated.
Crystallization and Data Collection
To prepare the A1DC:BH3 domain peptide complex for crystallization, pure
A1DC was mixed with excess BH3 domain peptide in a 1:1.5 molar ratio in
the presence of 2 mM TCEP (Sigma). The A1DC:BH3 domain complex was
then purified by size-exclusion chromatography using a Superdex 75 column
equilibrated in 20mMTris (pH 7.5), 150mMNaCl. A1DC:BH3 domain complex
crystals were grown at room temperature by hanging drop vapor diffusion from
drops containing 1 ml of protein with 1 ml of reservoir solution. Different crystal-
lization conditions were required to crystallize each A1DC complex. Unlabeled
A1DC:Puma crystals were obtained by mixing A1DC:Puma at 12.5 mg/ml with
0.1 M citric acid-KOH (pH 4.0), 15% (w/v) PEG 20,000, 0.65 M LiCl, 20% (v/v)16, 818–829, May 2008 ª2008 Elsevier Ltd All rights reserved 827
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A1DC:Puma at 15 mg/ml with 0.1 M citric acid-KOH (pH 4.35), 15% PEG
20,000, 0.4 M LiCl, 20% glycerol. A1DC:Bmf crystals were obtained by mixing
A1DC:Bmf complex at 10 mg/ml with 18% PEG 2,000, 0.88 M LiCl buffered
with 0.1Mcitric acid-KOH (pH 4.35). A1DC:Bak crystals were obtained bymix-
ing A1DC:Bak complex at 10 mg/ml with 0.1 M sodium citrate (pH 5.6), 0.3 M
(NH4)2SO4, 0.6 M Li2SO4. A1DC:Bid crystals were obtained by mixing
A1DC:Bid complex at 13 mg/ml with 0.1 M citric acid-KOH (pH 4.2), 18%
PEG 2,000, 0.4 M LiCl. For cryoprotection, 50% (v/v) well solution and 50%
(v/v) 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 30% (v/v) glycerol was used
for A1DC:Bmf and A1DC:Bak, and 50% well solution, 20% PEG 400, 30%
20 mM Tris-HCl (pH 7.5), 150 mM NaCl for A1DC:Bid and A1DC:Puma was
flash-frozen in its crystallization buffer. The A1DC:Puma BH3 domain MAD
data sets were collected at the National Synchrotron Light Source (NSLS) on
beamlines X29A and X12B. The A1DC:Bmf/Bak/Bid complex data sets were
collected using a Rigaku 007HF generator and R-axis IV++ image plate detec-
tor. The diffraction data were integrated using MOSFLM (Leslie, 1999), except
for the A1DC:Puma SeMet1 MAD data, which were integrated using HKL2000
(Otwinowski and Minor, 1997).
Structure Solution
The A1DC:Puma structure was solved by MAD. The SeMet substructure was
solved using SHELXS (Sheldrick et al., 1993) and refined usingMLPHARE from
the CCP4 suite (CCP4, 1994). After density modification using DM, the model
was built manually using Coot (Emsley and Cowtan, 2004). Subsequently,
higher-resolution SeMet A1DC:Puma data were obtained (A1:Puma SeMet 2)
and the previously built model was refined with the new data. After multiple
cycles of building and refinement with REFMAC5 (Murshudov et al., 1997),
translation/libration/screw (TLS) refinement was used to improve the model.
Each protein chain was assigned to a TLS group. Noncrystallographic symme-
try averaging was not used at any stage during refinement. Data collection and
refinement statistics are shown in Table 1.
The A1DC:Bmf/Bak/Bid BH3 domain complexes were solved by molecular
replacement. The A1 search model was derived from one molecule of A1 from
the A1DC:Pumamodel, with all side chains that contact the PumaBH3 domain
and the peptide itself removed tominimizemodel bias. PHASER (McCoy et al.,
2005) was used to locate one copy of the search model in the asymmetric unit.
For each structure, a solution with a significant Z score was obtained and
refined with REFMAC, followed by cycles of building with Coot and refinement.
TLS refinement was used for the final rounds as for the A1DC:Puma structure.
Figures were generated using PyMOL (DeLano, 2002).
Structure Comparisons
Structures of different molecules were superimposed with the program TOP
(Lu, 2000). However, superimpositions involving the A1DC:BH3 domain com-
plexes were performed in two stages using the CCP4 program LSQKAB. In an
initial round, residues from helices 1, 4, 5, and 6 (residues 9–20, 70–77, 86–104,
and 115–128) were used to superimpose A1DC:Puma CD/Bmf/Bak/Bid onto
the A1DC:Puma A chain. These overlaid structures were then input into a cus-
tom program which calculated for each residue the sum of the differences
between the mean Ca position and the Ca position for that residue in each
structure. This provided a measure of the similarity of each residue position
over all the structures. A second round of alignment was then performed
optimizing the superimposition of these similar regions. The second round of
alignment was performed using residues from helices 1, 5, 6, and 7 (residues
9–19, 84–102, and 118–139). The output from this second round of alignment
was then used in subsequent comparisons.
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